The pandemic underscored the dangers of lengthy biotech and pharma supply chains, but there are strategies for better quality control transparency.
In today’s global economy, supply chains that stretch around the world are the norm. Sourcing materials overseas yields cost efficiencies that often outweigh the risks involved. Those risks were highlighted by the COVID-19 pandemic, when restrictions on travel brought supply chains to a screeching halt. And the longer your chain is, the more severe the ripple effects of bottleneck after bottleneck will be.
“Pre-pandemic, there had been a move toward a global approach to the sourcing of materials. During the pandemic, that approach backfired. Domestic manufacturers weren’t able to get the raw materials they needed into the U.S. in order to make products,” said Kate Klaus, senior risk management attorney, FDA specialist, Medmarc.
Today, although the public health emergency is resolved, some negative effects of the pandemic-era supply chain challenges still remain.
In the biotech and pharmaceutical industries, the primary concerns surround…
